These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36892582)

  • 1. The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma.
    Schober SJ; Schoening C; Eck J; Middendorf C; Lutsch J; Knoch P; von Ofen AJ; Gassmann H; Thiede M; Hauer J; Kolk A; Mantwill K; Gschwend JE; Burdach SEG; Nawroth R; Thiel U; Holm PS
    Clin Cancer Res; 2023 May; 29(10):1996-2011. PubMed ID: 36892582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.
    Schober SJ; Thiede M; Gassmann H; von Ofen AJ; Knoch P; Eck J; Prexler C; Kordass-Wally C; Hauer J; Burdach S; Holm PS; Thiel U
    Front Immunol; 2024; 15():1330868. PubMed ID: 38318175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus.
    Koch J; Schober SJ; Hindupur SV; Schöning C; Klein FG; Mantwill K; Ehrenfeld M; Schillinger U; Hohnecker T; Qi P; Steiger K; Aichler M; Gschwend JE; Nawroth R; Holm PS
    Nat Commun; 2022 Aug; 13(1):4689. PubMed ID: 35948546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.
    Klawitter M; El-Ayoubi A; Buch J; Rüttinger J; Ehrenfeld M; Lichtenegger E; Krüger MA; Mantwill K; Koll FJ; Kowarik MC; Holm PS; Naumann U
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer.
    Lichtenegger E; Koll F; Haas H; Mantwill K; Janssen KP; Laschinger M; Gschwend J; Steiger K; Black PC; Moskalev I; Nawroth R; Holm PS
    Hum Gene Ther; 2019 Jan; 30(1):44-56. PubMed ID: 29916265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells.
    von Ofen AJ; Thiel U; Eck J; Gassmann H; Thiede M; Hauer J; Holm PS; Schober SJ
    Front Oncol; 2024; 14():1304374. PubMed ID: 38357194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
    Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells.
    Czolk R; Schwarz N; Koch H; Schötterl S; Wuttke TV; Holm PS; Huber SM; Naumann U
    Int J Mol Med; 2019 Oct; 44(4):1484-1494. PubMed ID: 31432139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
    Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
    Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma.
    Xiao J; Liang J; Fan J; Hou P; Li X; Zhang H; Li K; Bu L; Li P; He M; Zhong Y; Guo L; Jia P; Xiao Q; Wu J; Peng H; Li C; Xing F; Guo D
    Cancer Res; 2022 Sep; 82(18):3359-3374. PubMed ID: 35792620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.
    Yan Y; Li S; Jia T; Du X; Xu Y; Zhao Y; Li L; Liang K; Liang W; Sun H; Li R
    Tumour Biol; 2015 Jun; 36(6):4535-43. PubMed ID: 25627006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter.
    Cheng PH; Rao XM; Duan X; Li XF; Egger ME; McMasters KM; Zhou HS
    J Mol Med (Berl); 2015 Feb; 93(2):211-23. PubMed ID: 25376708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy.
    Lv P; Liu X; Chen X; Liu C; Zhang Y; Chu C; Wang J; Wang X; Chen X; Liu G
    Nano Lett; 2019 May; 19(5):2993-3001. PubMed ID: 30964695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
    Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
    Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.